All
The Week of May 13 in Review
The week of May 13 in review, featuring stories and videos on cabozantinib in medullary thyroid cancer, biomarkers in prostate cancer, and SAR302503 in myelofibrosis.
ASCO 2013 Abstract Roundup
Abstracts published in the Annual Meeting Proceedings Part I featuring late-stage data on ibrutinib, eribulin, regorafenib, sipuleucel-T, lambrolizumab, palbociclib, and more.
ASCO Highlights 7 Studies in Advanced Release
ASCO highlighted studies on treatment with ipilimumab and nivolumab in advanced melanoma, radiation in NSCLC, and idelalisib in chronic lymphocytic leukemia.
FDA Approves Radium-223 for Advanced Prostate Cancer
Radium RA 223 dichloride has been approved by the FDA for the treatment of symptomatic metastatic castration-resistant prostate cancer (mCRPC) that has spread to the bones but not to any other organs.
The Week of May 6 in Review
The week of May 6 in review, featuring stories and videos on cabozantinib in medullary thyroid cancer, biomarkers in prostate cancer, and SAR302503 in myelofibrosis.
Researchers Identify Potentially Druggable Targets in Acute Myeloid Leukemia
Acute myeloid leukemia (AML), the most common acute form of leukemia in adults, is potentially driven by at least one genetic mutation in nearly all cases.
Mechanism of Action: Cetuximab
Cetuximab is an epidermal growth factor receptor inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer.
Dacomitinib Shows Promising Activity in EGFR-Mutated and HER2-Mutated NSCLC
Nearly three-fourths of patients with previously untreated advanced NSCLC with specific mutations of EGFR experienced one full year of PFS when given the investigational therapeutic agent dacomitinib.
